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Background: Accelerated intermittent Theta Burst Stimulation (aiTBS) has been shown to be an effective
antidepressant treatment. Although neurobiological changes shortly after this intervention have been
reported, whether aiTBS results in structural brain changes must still be determined. Furthermore, it
possible that rapid volumetric changes are driven by factors other than neurotrophic processes.
Objectives: We examined whether possible grey matter volumetric (GMV) increases after aiTBS treat-
ment could be driven by increased brain perfusion, measured by Arterial Spin Labeling (ASL).
Methods: 46 treatment-resistant depressed patients were randomized to receive 20 sessions of active or
sham iTBS applied to the left dorsolateral prefrontal cortex. All sessions were delivered over 4 days at 5
sessions per day (trial registration: http://clinicaltrials.gov/show/NCT01832805). Patients were scanned
the day before starting stimulation and three days after aiTBS.
Results: There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to
HRSD changes after active aiTBS, but not after sham stimulation. These GMV increases became more
pronounced when accounting for changes in cerebral perfusion.
Conclusions: Active, but not sham, aiTBS, resulted in acute volumetric changes in parts of the left dentate
gyrus, suggesting a connection with adult neurogenesis. Furthermore, taking cerebral perfusion mea-
surements into account impacts on detection of the GMV changes. Whether these hippocampal volu-
metric changes produced by active aiTBS are necessary for long-term clinical improvement remains to be
determined.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Major depression is a common, often treatment resistant, psy-
chiatric disorder affecting hundreds of millions worldwide. Besides
its psychological sequalae, major depression results in several
functional and structural brain abnormalities. Structural changes,
such as grey matter decreases, have been consistently reported andr Inc. This is an open access articleare mostly found in the frontal cortices and the hippocampal re-
gions [1,2].
New treatment applications have been introduced and repeti-
tive transcranial magnetic stimulation (rTMS) is now recognized to
be a safe and effective treatment strategy in treatment-resistant
depression (TRD) [3]. Furthermore, when applied to the left
dorsolateral prefrontal cortex (DLPFC), several studies found that
the clinical effects were accompanied by grey matter volume
(GMV) increases in the temperomedial brain areas, including the
hippocampus [4e7]. Similar volumetric changes in hippocampal
areas have been observed following electroconvulsive therapy
(ECT), another noninvasive neurostimulation intervention. Of note,
there does not appear to be an association between the extent ofunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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Compared to the 20e30% remission rate found with the classical
daily applied rTMS protocols [10], remission rates with ECT are
often in the range of 48e70% in TRD [11e13].
A main objective in developing accelerated (a)rTMS has been to
enhance the speed of clinical improvement to be more comparable
to that obtained with ECT [14]. With arTMS, the number of pulses
per session or the number of daily sessions is markedly increased,
so that a given patient receives a similar number of total pulses
spread over a significantly shorter time period [15]. Encouragingly,
arTMS and classical daily rTMS appear to be quite similar in clinical
outcomes [16], indicating that the major advantage of accelerated
stimulation protocols is a shorter treatment duration. Given that
the clinical outcomes of high frequency (HF) rTMS and intermittent
theta burst stimulation (iTBS) in TRD seem to be quite similar [17],
here we have combined the accelerated protocol with iTBS, pro-
ducing aiTBS, delivering a similar amount of pulses over a shorter
time period.
In this sham-controlled brain imaging study, in line with the
findings using classical daily rTMS protocols, we evaluated whether
20 sessions of aiTBS influence GMV in TRD patients. Given that all
stimulation was delivered within only 4 days (5 sessions per day) -
a relatively short time to induce neuroplastic changes [18] - we also
evaluated whether potential GMV changes could be driven by
changes in brain perfusion. A topic receiving growing interest, also
in ECT literature [19]. Moreover, regional variations in both venous
and arterial density may correlate with cortical thickness [20].
Arterial spin labelling (ASL) is a non-invasive fMRI technique
that uses arterial water as an endogenous tracer, providing reliable
absolute quantification of regional cerebral blood flow (rCBF) [21].
ASL-fMRI is particularly well suited for multi-session longitudinal
studies and has successfully been used to examine the neurobio-
logical mechanisms of antidepressant response to ECT [22]. The
effects of GMV on rCBF - or the reverse - has been examined in a
variety of neuropsychiatric disorders [23e26]. However, when
comparing structural and functional measures from disparate im-
aging modalities (e.g., MRI and PET), one must rely on simple
region-of-interest type analyses, which do not allow the voxel-by-
voxel comparisons necessary to answer more sophisticated
neuroscience questions [27]. To overcome these limitations, and to
examine GMV and perfusion within the same brain voxels we used
robust Biological Parametric Mapping (BPM) software, widely used
for integrative analysis of different neuroimaging (functional or
structural) modalities [28]. This approach has already been suc-
cessfully applied in psychiatric research (e.g. Refs. [29,30]).
We hypothesized that active and not sham aiTBS would result in
GMV increases particularly in hippocampal subregions. Given the
short time period between the scans, i.e., one week, we determined
whether cerebral perfusion increments might have driven GMV
increases in the specific subregions.
Methods and materials
This study (http://clinicaltrials.gov/show/NCT01832805) was
approved by the local ethics committee of the Ghent University,
and all participants provided written informed consent. This study
was part of a larger project investigating the effects of aiTBS on
various neurocognitive markers.
Subjects
Right-handed TRD patients (33 females, 13 males; age ¼ 41.48
years, SD¼ 11.81) with a complete set of the baseline structural and
perfusion scans were included. The full behavioral data were re-
ported by Duprat et al. [31]. In brief, patients were selected usingtheMini-International Neuropsychiatric Interview (MINI [32]), and,
as described by Rush et al. [33], all were at least Stage I TRD (i.e.,
they had insufficient benefit from at least one adequate antide-
pressant trial). Exclusion criteria included a history of epilepsy or
neurosurgical intervention, pacemaker, metallic or magnetic ob-
jects in brain, and alcohol dependence, ECT, or any suicide attempt
within the past 6 months. Patients with bipolar or psychotic major
depressive episodes were also excluded. After a washout period,
except for long-standing benzodiazepines, patients were free of
psychotropic medications for a minimum of two weeks before the
first MRI scan and the first aiTBS session. Depression symptom
severity was assessed with the 17-item Hamilton Rating Scale for
Depression (HRSD [34]) by a certified psychiatrist not related to the
study and masked to the randomized treatment assignment.
In this sham-controlled, brain imaging study, we focused pri-
marily on the first part of the stimulation protocol (see Fig. 1). This
allowed us to examine the acute effects of aiTBS on imaging mea-
sures using a purely between-subjects design, uncontaminated by
the issues intrinsic to use of a crossover. Restricting the analyses to
the first phase limited the extent of patient unmasking to treatment
condition, given the intrinsic differences in sensations produced by
the active and the sham stimulation protocols. However, to explore
whether aiTBS administered after the crossover would result in
similar or other GMV changes, we also analyzed the MRI data be-
tween T2 and T3 as secondary outcomes (see Supplemental Fig. 1).
iTBS procedure
Accelerated intermittent TBS stimulation was applied using a
Magstim Rapid2 Plus1 magnetic stimulator (Magstim Company
Limited, Minneapolis, USA) with an active and sham, figure-of-
eight, cooled coil. The Magstim 70 mm Double Air Film sham coil
is identical in all aspects to its active variant, but without stimu-
lation output. The Air Film sham coil produces similar sensory ex-
periences, but it does not deliver active stimulation of cortical
neurons. Not including brain anatomical information of each
participant when identifying the target zone may result in stimu-
lation outside the intended area. In this study the left DLPFC was
targeted based on the individual structural MRI [35], using the
Brainsight neuronavigation system (Brainsight™, Rogue Resolu-
tions, Inc.). The left DLPFC was visually located on the 3D surface
rendering of the brain based on the known gyral morphology, with
the center part of themid-prefrontal gyrus serving as the left DLPFC
target (Brodmann 9/46). The treatment protocol consisted of 20
iTBS sessions spread over 4 days (five sessions per day), adminis-
tering a total of 32,400 pulses (see Fig. 1). Stimulation intensity was
fixed at 110% of resting motor threshold, and patients received 1620
pulses per session in 54 triplet bursts with a train duration of 2 s
and cycling period of 8 s. There was a pause of approximately
15 min between consecutive sessions. Patients were blindfolded,
fitted with earplugs, and they were kept blind to of the active or
sham stimulation condition.
Brain imaging procedures
Scanning was performed on a Siemens 3T TrioTim MRI scanner
(Siemens, Erlangen, Germany) with a 32 channel SENSE head coil.
Patients were instructed not to drink coffee or smoke the day of the
imaging procedures. Scanning was performed on Monday morning
between 9 and 12 a.m. For the anatomical localization of the left
DLPFC participants underwent a T1-weighted MRI brain scan (3D-
TFE, TR/TE ¼ 2530/2.58; flip angle ¼ 7; FOV ¼ 220  220mm2;
resolution ¼ 0.9  0.9  0.9 mm3; number of slices ¼ 176). Multi-
delay pulsed arterial spin labeled (pASL) images with a 3D GRASE
readout were obtained with the following parameters: TR ¼ 3.4s,
Fig. 1. Flow chart of the accelerated iTBS experimental procedure.
After a washout period, all MDD patients were at least two weeks antidepressant (AD) free before they underwent a first MRI scan at time T1 (baseline). Hereafter, patients were
randomly divided into two groups to receive 20 sessions of real or sham accelerated iTBS treatment respectively. aiTBS treatment was spread over four succeeding afternoons (5
daily sessions). A second MRI was performed exactly 1 week after the first week (time T2) and a third one exactly after 2 weeks (time T3). At each of these time points all patients
were clinically assessed. However, for the current study hypothesis, although in the second week, strictly the same treatment schedule was followed but with a change of
stimulation: line AB ¼ a TRD patient who first received active aiTBS now received sham; line BA ¼ a patient who first received sham treatment now received the active session,
these data were not included in the analyses.
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changing from 250 to 3000 ms in steps of 250 ms, resulting in
twelve pairs of slice-selective (SS) and non-selective (NS) images.
All MR images were aligned to the AC-PC before scanning. During
the ASL measurements, participants were asked to stay awake with
their eyes closed.
The longitudinal voxel-based morphometry analysis was per-
formed using the Computational Anatomy Toolbox (CAT12, http://
dbm.neuro.uni-jena.de/cat/). After intra-subject realignment, the
mean map of the realigned images was created for each subject.
Bias correction and spatial segmentation were then performed on
all time points and mean maps. The spatial normalization param-
eters estimated from themean image were applied to the images of
all time points. Finally, the normalized grey matter images (voxel
size: 1.5  1.5  1.5 mm3) were modulated and smoothed using 8-
mm full-width half-maximum Gaussian filter.
The pASL images were pre-processed and analyzed using SPM12
and FSL. The pASL images were realigned to correct for motion and
registered to the anatomical image using SPM. Then 12 perfusion-
weighted images were generated by surround subtraction. The
perfusion-weighted images were submitted for CBF estimation
using ‘oxford_asl’ in FSL. The partial volume correction was applied
in the generated CBF maps [36]. Global mean normalization was
applied to the CBF data. Finally, the CBF maps were spatially
normalized into MNI space and smoothed with an 8 mm full-width
half-maximum Gaussian kernel.Statistical analysis
First, to investigate the relations between morphometric
changes and change in depression severity, we conducted a voxel-wise multiple regression analysis. Age, gender, total intracranial
volume (TIV), and change in HRSD scores (HRSDt1eHRSDt2) were
the covariates, while the change in GMV (GMVt2eGMVt1) was the
dependent variable. Second, to answer our main research question,
and to exclude the possibility that morphometric changes in GMV
induced by aiTBS were a result of concomitant perfusion change,
the above analysis was performed again, adding voxel-wise delta
ASL (ASLt2eASLt1) maps as covariates, using the Robust Biological
Parametric Mapping (BPM) toolbox ([28]; https://www.nitrc.org/
projects/rbpm/). Casanova and co-workers [27] developed this
BPM toolbox for multimodal image analysis. This software has been
used widely for integrative analysis of different neuroimaging
(functional or structural) modalities, further expanded to robust
BPM, including robust regression and robust inference reducing
sensitivity to outliers without substantial degradation in power
[28].
Results were considered statistically significant using a whole-
brain FWE cluster corrected threshold of p < 0.05, and uncorrec-
ted voxel-wise p-values < 0.001 by the cluster-forming threshold of
30 voxels.Results
Behavioral results
After randomization, twenty-two TRD patients received active
aiTBS and twenty-four TRD patients received sham aiTBS. Four
additional patients (2 active, 1 sham, 1 spontaneous remission
before starting the stimulation protocol) were included in the study
reporting therapeutic outcomes (total n ¼ 50) but were excluded
here due to incomplete imaging data (n ¼ 1), retrospective primary
Fig. 2. Left hippocampus.
Upper left) Significant increases in left hippocampal grey matter volumes after active
aiTBS (T1-T2). Upper right) Detailed overview of the different left hippocampal sub-
regions including the significant increased left hippocampal volumetric increases after
active aiTBS. Lower left and right) Detailed sagittal and coronal view of the significant
left dentate gyral cluster using the SPM Anatomy Toolbox. L ¼ left, R ¼ Right. CA Cornu
Ammunis, DG: dentate gyrus, EC: entorhinal cortex, HATA: hippocampal amygdala
transition area, Subc: Subiculum.
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attempt in the first week of sham stimulation (n ¼ 1). The active
and sham aiTBS groups did not differ in age, gender, the duration of
the current depressive episode, benzodiazepine intake, depression
severity, and motor threshold (all p’s > 0.05) (see Table 1). A
repeated measures ANOVA was performed with HRSD depression
severity scores at T1 and T2 with randomized treatment condition
as the between-subjects factor and time as the repeated measure.
There was a main effect of time, F(1, 44)¼ 12.26, p < 0.01, but not of
treatment group F(1, 44) ¼ 0.95, p ¼ 0.34, and the interaction was
not significant, F(1, 44)¼ 1.08, p¼ 0.30. Both the active aiTBS group
[T1: 21.05 (4.69), T2: 16.82 (7.29), t(21) ¼ 2.80, p ¼ 0.01] and the
sham aiTBS group [T1: 21.50 (6.25), T2: 19.21 (4.87), t(21) ¼ 2.04,
p ¼ 0.05] had modest, but significant, decreases in HRSD scores
over the one-week interval.
Brain imaging results
Before controlling for perfusion values and using a strict
threshold for statistical significance (p < 0.001), we did not find a
significant difference between the randomized treatment condi-
tions in change in GMV across the two time points. Changes in GMV
over this time period were also not associated with change in
depression severity. Of note, we found GMV increases in the left
hippocampal areas related to changes in depression severity
without considering brain perfusion as a covariate, but at a lower
significance threshold p < 0.005 (see Supplemental Fig. 2).
When accounting for change in ASL perfusion values, there was
a significant cluster of increased left hippocampal GMV related to
HRSD changes after active aiTBS, but not after sham stimulation.
The exact anatomical localization of this significant cluster
(p < 0.05, FWE-corrected) was obtained with the SPM Anatomy
toolbox [38,39]. We found that the 77% of the major volumetric
increases were in the left dentate gyrus, 13.3% of GMV increases
were found in the left cornu ammonis (CA) subfields CA1, and 1.8%
in the left CA2 (see also Fig. 2). To ensure that these GMV increases
within this significant cluster in the left dentate gyrus were not
related to perfusion changes, we extracted the individual perfusion
values at T1 and T2. A paired t-test confirmed that perfusion within
this left dentate gyral cluster was not significantly different before
(0.13 (0.06)) and after (0.11 (0.03)) active aiTBS t(21) ¼ 1.58,
p ¼ 0.13, nor before (0.11 (0.07)) and after (0.09 (0.05)) sham aiTBS
t(23) ¼ 1.38, p ¼ 0.18. Thus, while the perfusion changes were not
themselves statistically significant, controlling for their variability
improved sensitivity in detecting between-group GMV changes. Of
note, when change in HRSD scores served as the dependent vari-
able and the other biological measures (age, gender, TIV, delta GMV,
and delta ASL) as independent variables, we also found that the left
hippocampal area/dentate gyrus is the common region related to
changes in depression severity scores (see also Supplemental
Fig. 3).
To verify that hippocampal GMV changed in a similar way in
patients who first received sham treatment (T1-T2) and in the
second week now active aiTBS (T2-T3), we examined GMV values
after crossing over to active aiTBS. Although only with a lowerTable 1
Baseline differences between the active and the sham aiTBS group.
Active aiTBS (n ¼ 22)
Age 40.09 (11.45)
Gender (Male: Female) 6:16
Duration depressive episode (years) 4.37 (6.69)
rMT (%) 60.88 (8.01)
Baseline depression severity 21.50 (6.25)significance threshold (p < 0.005), we found similar GMV increases
in the dentate gyrus whether or not we included ASL perfusion
values as covariates (see Supplemental Fig. 4). Change in GMV in
the left hippocampal subregions were independent of change in
symptom scores.
Discussion
In a well-defined sample of TRD patients, we determined
whether 20 sessions of iTBS d delivered to the left DLPFC in an
accelerated fashion d produces GMV change. Importantly, to
ensure that such volumetric change was not simply driven by
change in rCBF, ASL scans were collected at the same time as the
volumetric measurements. Four days of active, but not sham, aiTBS
resulted in a significant volumetric increase in the left dentate
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could not be attributed to change in local perfusion. Furthermore,
those patients who received sham aiTBS in the first week and active
aiTBS after the crossover in the second week displayed a similar
GMV increase in the left hippocampus, although at a lower signif-
icance threshold (p < 0.005). This volumetric effect, related to
clinical improvement, also could not be attributed to changes in
perfusion (see Supplemental Fig. 4).
Somewhat unexpectedly, when not controlling for change in
ASL values, we did not observe significant GMV change after the
first week of active or sham aiTBS. This was likely due to the
stringent statistical threshold we used with whole brain correction.
Indeed, when using a lower significance threshold, a left hippo-
campal GMV increase predominantly in the dentate gyrus was
observed after active aiTBS only (see Supplemental Fig. 1) without
controlling for perfusion effects. Adding ASL values to the analysis
as covariate produced clearer results regarding GMV change. This
suggests that the assessment of cerebral perfusion can reduce noise
in GMV measures when examining between-group differences in
longitudinal volumetric effects. From a neuroanatomical point of
view when voxel-wise examining GMV and perfusion this is not a
contradictory observation. Arterioles penetrate the grey matter
carrying blood and oxygen traversing all cortical layers into the
capillary bed [40], leaving no portion of tissue without perfusion,
with every neuron lying within 15 mm of a brain capillary [41]. It is
estimated that a cortical volume of 1 cm3 contains approximately
ten million vessels [42]. Increased rCBF (via vessel vasodilation)
may induce an overestimation of cortical thickness and grey matter
volume [43]. By controlling for individual differences in change in
perfusion can lead tomore accurate estimation of cortical thickness
or GMV change.
Our observations are consistent with the recent open-label
findings of Hayasaka et al. [5] and Noda et al. [7], who observed
left lateralized hippocampal GMV increases following classical daily
HF-rTMS applied to the left DLPFC. Furthermore, our findings are
also consistent with repeated observations that ECT results in
hippocampal GMV increases [19,44,45]. Our findings indicate that
left hippocampal GMV increases occur after active aiTBS stimula-
tion and not sham aiTBS and are detectable after only 4 days of
aiTBS. It has been proposed that the (bilateral) hippocampal volume
increases found after ECT may be an epiphenomenon, and that
hippocampal enlargement may be a consequence seizure induction
that is independent of its therapeutic effects [45]. Given that (r)TMS
applications do not require seizures, our current aiTBS findings are
of interest in demonstrating in a sham-controlled manner that iTBS
produces a similar GMV increase. Since the sample showed only
modest symptom change over the one-week measurement period,
and the degree of symptom reduction did not covary with the
volumetric change, it is also possible that these volumetric effects
of iTBS are epiphenomenawith respect to therapeutic mechanisms.
Alternatively, these volumetric effects may mark necessary com-
ponents of the therapeutic process. At this stage, we can only state
that the GMV changes we observed should not be viewed as an
artifact of changes in cerebral perfusion.
It is of interest that the left hippocampal volumetric increases
after 4 days of active aiTBS were principally located in the dentate
gyrus (Fig. 2). This subregion is an integral portion of the larger
functional brain system referred to as the hippocampal formation
[46]. Dentate granule cells are the only neurons thought to be
continuously generated into adulthood [47]. It is noteworthy that
ECT in animals induces neurogenesis specifically in granule cells of
the dentate gyrus [48,49] and human studies have noted volu-
metric increases in the same subregion following ECT in the human
[50e52].Largely based on studies blocking antidepressant effects in an-
imal models, it has been hypothesized that hippocampal neuro-
genesis is an important and perhaps necessary component of
antidepressant therapeutic processes [53e56]. Given that
decreased neurogenesis in the dentate gyrus and glutamatergic
neurotransmission dysfunction appear to contribute to the devel-
opment of depression [57], ketamine, a non-competitive NMDA
glutamate receptor channel blocker, produces a rapid onset of an-
tidepressant responses, resulting in fast changes in synaptic func-
tion and plasticity [58]. Indeed, because the DLPFC and the
hippocampus are synaptically connected via (glutaminergic) py-
ramidal neurons [59], from an electrophysiological point of view,
aiTBS applied to the left DLPFCmay also directly influence neuronal
activity in hippocampal regions. Of note, prefrontal and hippo-
campal postsynaptic serotonin 5-HT2A receptor density changes
have been linked to clinical response with classic daily rTMS and
such changes are thought to be related to neuroplastic processes
[60].
Our study had important limitations. The single-masked, ran-
domized control trial did not produce the hypothesized differences
in clinical outcomes for the groups randomized to active or sham
aiTBS, although overall rates of response and remission were not
insubstantial (see Duprat et al. [31] for a complete overview of the
clinical results). While this was an unexpected behavioral result, it
helped to further dissociate the volumetric and therapeutic effects.
The randomized groups differed in volumetric changes, but not in
clinical outcome. Neuropsychological assessment was not con-
ducted to evaluate potential (positive or negative) effects of aiTBS
on cognitive processes putatively related to changes in neuro-
plasticity in the hippocampal formation. Additional scanning pro-
tocols were not conducted to examine the molecular basis of the
left dentate gyrus neuroplastic process, and specifically whether
the volumetric effects were mediated by impact on the seroto-
nergic/glutamatergic transmission. Our aiTBS protocol was
designed to produce rapid clinical and volumetric effects, with the
time frame too brief (1 week) for neurogenesis to result in mature,
functional neurons. Thus, any link between “neurogenesis” and
clinical improvement must be mediated by earlier elements in the
cascade that produces neuroplasticity, such as increased release of
brain-derived neurotrophic factor (BDNF) and other neurotrophic
factors. Unfortunately, tissue samples were not collected at the
relevant time points, leaving it an open question whether the left
hippocampal GMV increases observed 3 days after the active aiTBS
protocol were driven by early components of neuroplastic pro-
cesses. Furthermore, no follow-up scans or other assessments were
performed beyond the stimulation protocol reported here. In
addition, cerebral perfusion change was not found to be associated
with GMV change. However, we did not examine potential mo-
lecular or microstructural factors that could impact on either
measure [22]. For instance, inflammatory processes are associated
with increased blood flow [22] and decreased volumetric changes
[61] in the depressed state. Finally, the time intervals between
sessions using accelerated rTMS paradigms may impact on out-
comes [62], and our 15-min intersession interval may have been
too brief to optimally alter synaptic plasticity, as 60-90-min inter-
session iTBS intervals may induce stronger synaptic plasticity ef-
fects [63]. Nevertheless, our study clearly shows volumetric
increases in specific hippocampal areas after 4 days of active
stimulation delivered on 5 daily sessions with an intersession in-
terval of 15 min.
In summary, active, but not sham, aiTBS results in significant
GMV increases in the left dentate gyrus, part of the hippocampal
formation. These volumetric increases could not be attributed to
changes in cerebral perfusion. On the other hand, including ASL
measurements in our analysis made detection of the volumetric
C. Baeken et al. / Brain Stimulation 13 (2020) 1211e12171216changes more sensitive, suggesting that it is useful when investi-
gating GMV in depressed patient samples to take cerebral perfusion
into account. Indeed, multimodal brain imaging may not only help
to increase our insights into the neurobiology of TRD but also into
the working mechanisms of non-invasive brain stimulation
methods, such as rTMS [64]. For instance, it would be interesting to
investigate whether there were any changes in white matter isot-
ropy in the pathways related to DLPFC-hippocampal connectivity.
Although our observations suggest that, like psychopharmaco-
therapy and ECT, active aiTBS induces neuroplasticity and changes
brain structure however, the exact mechanisms subserving this
neuroplastic effects, its relation to neurotransmitter systems, and
its functional significance remain to be determined. Nevertheless, it
is striking that only four days of active aiTBS induces GMV increases
in areas of the brain well documented to be involved in the path-
ophysiology of TRD.
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